The anti‐PD‐L1 nanobody binds to the PD‐L1 molecule with high affinity and enhances the anti-tumour immune response by blocking PD-1/PD-L1 signalling and promoting IFN-γ secretion [29, 44]. Here, PDCD1 is linked to neoplasm.